Brainstorm

Public Builds Out its Editorial and Content Network for Retail Investors

Retrieved on: 
Montag, Mai 13, 2024
Partnership, Axios, News, Education, Heart, The Rundown, Public, Brainstorm, Bread, Editorial, Apple, ETF, Ark Invest, Universal indicator, Robotics, Humour

NEW YORK, May 13, 2024 /PRNewswire/ -- Public , the investing platform that lets members invest in stocks, ETFs, crypto, bonds, options, and alternative assets, announces the expansion of its editorial and content network for retail investors by launching the Public Media Network .

Key Points: 
  • NEW YORK, May 13, 2024 /PRNewswire/ -- Public , the investing platform that lets members invest in stocks, ETFs, crypto, bonds, options, and alternative assets, announces the expansion of its editorial and content network for retail investors by launching the Public Media Network .
  • This year, Public is adding more hosts and shows to its roster and revamping the editorial content.
  • "Public's editorial and content network demystifies the markets, the US economy, and business trends, allowing retail investors to easily access financial education."
  • Public's content and editorial networks are editorially independent of the company and provide retail investors with top business and finance news, expert insights, and helpful context on the public markets.

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

Retrieved on: 
Mittwoch, Mai 8, 2024
Baylor University, SPA, Ovarian cancer, Food, Statistics, Eli Lilly, Brainstorm, Science, Psychology, Patient, American Statistical Association, ALS, Eli Lilly and Company, Biogen, Therapy, COVID-19, Growth, International Biometric Society, Management

LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON’s board of directors since 2021.

Key Points: 
  • Dr. Lindborg assumes the leadership of IMUNON at a pivotal time.
  • Lindborg is uniquely qualified to take the reins as IMUNON’s President and CEO, bringing a track record of success in virtually every aspect of the work before the company,” said Michael H. Tardugno, IMUNON’s executive chairman.
  • We have benefited significantly from her counsel as a director, where she has played an integral role in establishing our strategic priorities.
  • Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen.

BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS

Retrieved on: 
Mittwoch, April 10, 2024
FDA, Inflammation, Cell, SPA, AFL, MD, Brainstorm, Doctor of Philosophy, Pathology, Patient, ALS, Neurology, CSF, Neuron, Biomarker, Drug development, Muscle & Nerve, Stem cell, Therapy, Pharmaceutical industry

NEW YORK, April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. The paper, entitled "Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes", can be found online through the Muscle and Nerve website. This study suggests that debamestrocel or NurOwn®, an investigational cell therapy, may impact key biomarkers in amyotrophic lateral sclerosis (ALS) that are predictive of disease progression.

Key Points: 
  • Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS.
  • NEW YORK, April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve.
  • This study suggests that debamestrocel or NurOwn®, an investigational cell therapy, may impact key biomarkers in amyotrophic lateral sclerosis (ALS) that are predictive of disease progression.
  • Stacy Lindborg, PhD, Co-Chief Executive Officer of BrainStorm Cell Therapeutics, added: "Biomarkers are becoming an increasingly important part of drug development in ALS.

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
Dienstag, April 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

Retrieved on: 
Montag, April 8, 2024
MD, Brainstorm, Webcast, Doctor of Philosophy

NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.

Key Points: 
  • A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time
    NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.
  • BrainStorm's President and Chief Executive Officer, Chaim Lebovits, Co-Chief Executive Officer, Stacy Lindborg, PhD and Chief Development Officer, Bob Dagher, MD, will present the update after which investment community questions will be answered.
  • The investment community may participate in the conference call by clicking the link below or dialing the following numbers:

Fortune Names New Editorial Leadership and Advisory Board for Brainstorm Tech Franchise Ahead of 2024 Summit in Park City, Utah, July 15 - 17

Retrieved on: 
Dienstag, April 2, 2024
Federal Reserve Bank, Editorial, Brex, Wiz, Profile (Marvel Comics), KPMG, Amazon, Y Combinator, Business Insider, Partnership, General partnership, Senior, Thought, Silicon, Cisco, Artificial general intelligence, Activision Blizzard, Losing My Mind, Burn, Brainstorm, Riot Games, Tech

NEW YORK, April 2, 2024 /PRNewswire/ -- Fortune Media announced Andrew Nusca as the new Editorial Director of its Brainstorm Tech franchise, the 23-year-old flagship event where the top technology and media leaders, operators, entrepreneurs, innovators, and influencers assemble for a dynamic exchange of ideas. Fortune also created a new advisory board for Brainstorm Tech – its BrainTRUST – to help power this year's summit in Park City, Utah, July 15 to 17.

Key Points: 
  • Fortune also created a new advisory board for Brainstorm Tech – its BrainTRUST – to help power this year's summit in Park City, Utah, July 15 to 17.
  • Maryam Banikarim, Managing Director, Fortune Live Media, responsible for the Brainstorm Tech global franchise, said: "We are thrilled to welcome Andrew back to Fortune.
  • Early confirmed sponsors for Brainstorm Tech 2024 include KPMG and the New York Stock Exchange, both returning as sponsors of the annual summit.
  • For more dates and information on the Brainstorm Tech 2024 summit: Fortune Brainstorm Tech 2024 .

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Montag, April 1, 2024
Neuroprotection, Research, Conference, Prejudice, Disease, SPA, ALS, Patient, Biomarker, Committee, Gene, MD, Biologics license application, Agency, Safety, Brainstorm, Poster, Therapy, Marketing, FDA, BLA, Episcopal conference, Food, Pharmaceutical industry

NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
  • We continue to believe that, if approved, NurOwn has the potential to be a valuable treatment option for ALS patients in need.
  • Stacy Lindborg, Ph.D., co-CEO BrainStorm commented, "We are acutely aware of the challenges faced by those afflicted with ALS.
  • In October 2023, Brainstorm announced a strategic realignment to enable accelerated development of NurOwn for the treatment of ALS.

Fortune Media Expands In The UK And Europe, Establishing The New Destination For Business Leaders Across The Region

Retrieved on: 
Mittwoch, März 20, 2024
Research, Editorial, Editing, Fortune (magazine), PRINT, Fidelity International, Corporate title, London Stock Exchange Group, Drum, AI, Memo, Schepers, Commercial director, LIVE, DIGITAL, Accenture, Brainstorm, The Wall Street Journal

LONDON, March 20, 2024 /PRNewswire/ -- Fortune Media announced today a significant expansion in the UK and Europe. The publication is adding several new top editorial and commercial executives to its European operations, including Alex Wood Morton as Executive Editor for Europe.

Key Points: 
  • Previously, he oversaw growth of the Forbes brand across Europe as the Managing Director and Europe Editor.
  • He will join Fortune Europe as Editorial Director, Leadership, spearheading CEO and leadership coverage, and developing an exclusive community of business leaders in Europe.
  • He'll convene events for the UK/Europe's C-Suite and share insights into how to shape business success in the UK and Europe.
  • Executive Editor Alex Wood Morton said: "Until now, the UK and Europe have lacked an editorial champion for big business.

Fortune Media Expands In The UK And Europe, Establishing The New Destination For Business Leaders Across The Region

Retrieved on: 
Mittwoch, März 20, 2024
Research, Editorial, Editing, Fortune (magazine), PRINT, Fidelity International, Corporate title, London Stock Exchange Group, Drum, AI, Memo, Schepers, Commercial director, LIVE, DIGITAL, Accenture, Brainstorm, The Wall Street Journal

LONDON, March 20, 2024 /PRNewswire/ -- Fortune Media announced today a significant expansion in the UK and Europe. The publication is adding several new top editorial and commercial executives to its European operations, including Alex Wood Morton as Executive Editor for Europe.

Key Points: 
  • Previously, he oversaw growth of the Forbes brand across Europe as the Managing Director and Europe Editor.
  • He will join Fortune Europe as Editorial Director, Leadership, spearheading CEO and leadership coverage, and developing an exclusive community of business leaders in Europe.
  • He'll convene events for the UK/Europe's C-Suite and share insights into how to shape business success in the UK and Europe.
  • Executive Editor Alex Wood Morton said: "Until now, the UK and Europe have lacked an editorial champion for big business.

Fortune Names Maryam Banikarim to Lead Its Most Powerful Women and Brainstorm Tech Franchises

Retrieved on: 
Donnerstag, März 7, 2024
Signals Network, International, School, Woman, Barnard College, New Yorker, Journalist, Education, MPW, NBCUniversal, Tech, Growth, Government, VCS, Public affairs, Brainstorm, Business school, Univision

NEW YORK, March 7, 2024 /PRNewswire/ -- Fortune Media announced today the appointment of Maryam Banikarim as Managing Director, Fortune Live Media.

Key Points: 
  • NEW YORK, March 7, 2024 /PRNewswire/ -- Fortune Media announced today the appointment of Maryam Banikarim as Managing Director, Fortune Live Media.
  • Banikarim will be responsible for the media company's prestigious Most Powerful Women (MPW) and Brainstorm Tech global franchises.
  • I couldn't be more excited to work with the talented group of journalists and professionals at Fortune to grow the Most Powerful Women and Brainstorm Tech franchises," said Banikarim.
  • Banikarim joins Fortune after being a guest co-chair of the 2023 Fortune Most Powerful Women summit and as a longtime member of the MPW community.